Clinical study of individualized antithrombotic strategy with aspirin based on the platelet function test after palliative surgery for congenital heart disease in children

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000036446

Enrollment

Unknown

Registered

2020-08-23

Start date

2020-03-01

Completion date

Unknown

Last updated

2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congential heart disease

Interventions

experimental group:Aspirin is administered individually based on platelet function test

Control group:Giving Aspirin with a consistent dose 3mg/kg/d

Eligibility

Sex/Gender

All

Age

0.1 Years to 6 Years

Inclusion criteria

Inclusion criteria: Children with congenital heart disease who underwent palliative surgery, aged from 1 month to 6 years.Sign the informed consent before enrollment.

Exclusion criteria

Exclusion criteria: 1. Congenital or acquired coagulation dysfunction; 2. Preoperative platelet count <50x10^9/L; 3. Suspected thrombus events before ASA administration

Design outcomes

Primary

Measure	Time frame
total rate of thromblic events and death;	—

Secondary

Measure	Time frame
incidence of bleeding events;	—

Countries

China

Contacts

Public ContactXu Wang

Fuwai Hospital, Chinese Academy of Medical Science; National Center for Cardiovascular Diseases

fwpicu@163.com+86 13701061512

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026